Fort Pitt Capital Group’s Lipocine LPCN Stock Holding History

Fort Pitt Capital Group’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,044	Closed	-$25K	–	171
2020 Q1	$25K	Buy	+3,044	New	+$24.1K	﹤0.01%	168

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return

BBVA

Banco Bilbao Vizcaya Argentaria Madrid, Spain $16.1B AUM 40.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Choreo LLC Rockford, Illinois $9.11B AUM 26.3% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Fort Pitt Capital Group's LPCN Position: Q2 2020 in Review

Fort Pitt Capital Group sold out of Lipocine (LPCN) in Q2 2020, closing a stake of 3,044 shares — an estimated $25K sold.

Fort Pitt Capital Group first reported a position in LPCN in Q1 2020 and held it in 1 quarter. The position peaked at $25K in Q1 2020. 33 funds tracked by Wall St. Rank hold LPCN as of Q2 2020.

Fort Pitt Capital Group reported no remaining Lipocine position as of Q2 2020 after selling out during the quarter.
Fort Pitt Capital Group sold 3,044 Lipocine shares in Q2 2020, an estimated $25K.
Fort Pitt Capital Group first reported a position in Lipocine in Q1 2020 and held it in 1 quarter.
Fort Pitt Capital Group's Lipocine position peaked at $25K in Q1 2020.
33 funds tracked by Wall St. Rank held Lipocine as of Q2 2020.

Based on Fort Pitt Capital Group's 13F filing for Q2 2020, filed 12 Aug 2020.